The influence of remimazolam on cardiac output in coronary artery bypass grafting

Phase 4

• Conditions: coronary artery disease

• Registration Number: ChiCTR2200056299
• Lead Sponsor: Beijing Anzhen Hospital, Capital Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.ASA physical status I-IV;<br>2.BMI 18-20 kg/m^2;<br>3.Aged above 18 years;<br>4.Prepare to have coronary artery bypass grafting under general anesthesia;<br>5.Selective operation.

Exclusion Criteria

1. Female in pregnancy or lactation and anyone prepare to give birth;<br>2. Having severe organ dysfunction in respiratory or circulation system or having abnormality in CBC and CMP;<br>3. Having severe mental illness or disease in nervous system;<br>4. Having benzodiazepines or opioids everyday in a month or once for two days;<br>5. Allergic or having contradiction using benzodiazepines, opioids, propofol, flumazenil, naloxone and their ingredients;<br>6. Ruled as patient with difficult airway: mallmapati score above III.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cardiac output;

Secondary Outcome Measures

Name	Time	Method
cardiac index;stroke volume;system vascular resistance index;blood pressure;heart rate;the amount of vasoactive drug;